These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22573538)

  • 1. Pharmaceutical aspects of the recombinant human serum albumin dimer: structural characteristics, biological properties, and medical applications.
    Taguchi K; Chuang VT; Maruyama T; Otagiri M
    J Pharm Sci; 2012 Sep; 101(9):3033-46. PubMed ID: 22573538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superior plasma retention of a cross-linked human serum albumin dimer in nephrotic rats as a new type of plasma expander.
    Taguchi K; Urata Y; Anraku M; Watanabe H; Kawai K; Komatsu T; Tsuchida E; Maruyama T; Otagiri M
    Drug Metab Dispos; 2010 Dec; 38(12):2124-9. PubMed ID: 20855459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-linked human serum albumin dimer has the potential for use as a plasma-retaining agent for the fatty acid-conjugated antidiabetic drugs.
    Taguchi K; Chuang VT; Yamasaki K; Urata Y; Tanaka R; Anraku M; Seo H; Kawai K; Maruyama T; Komatsu T; Otagiri M
    J Pharm Pharmacol; 2015 Feb; 67(2):255-63. PubMed ID: 25556343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human serum albumin dimer has high blood circulation activity and low vascular permeability in comparison with native human serum albumin.
    Matsushita S; Chuang VT; Kanazawa M; Tanase S; Kawai K; Maruyama T; Suenaga A; Otagiri M
    Pharm Res; 2006 May; 23(5):882-91. PubMed ID: 16715378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights into in vitro amyloidogenic properties of human serum albumin suggest considerations for therapeutic precautions.
    Sharma N; Sivalingam V; Maurya S; Prasad A; Khandelwal P; Yadav SC; Patel BK
    FEBS Lett; 2015 Dec; 589(24 Pt B):4033-8. PubMed ID: 26554815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles.
    Kratz F
    J Control Release; 2008 Dec; 132(3):171-83. PubMed ID: 18582981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Albumin clusters: structurally defined protein tetramer and oxygen carrier including thirty-two iron(II) porphyrins.
    Komatsu T; Oguro Y; Nakagawa A; Tsuchida E
    Biomacromolecules; 2005; 6(6):3397-403. PubMed ID: 16283771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S-Nitrosated human serum albumin dimer is not only a novel anti-tumor drug but also a potentiator for anti-tumor drugs with augmented EPR effects.
    Ishima Y; Chen D; Fang J; Maeda H; Minomo A; Kragh-Hansen U; Kai T; Maruyama T; Otagiri M
    Bioconjug Chem; 2012 Feb; 23(2):264-71. PubMed ID: 22225412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative studies on drug binding to the purified and pharmaceutical-grade human serum albumins: Bridging between basic research and clinical applications of albumin.
    Ashrafi-Kooshk MR; Ebrahimi F; Ranjbar S; Ghobadi S; Moradi N; Khodarahmi R
    Biologicals; 2015 Sep; 43(5):333-43. PubMed ID: 26254507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human serum albumin: from bench to bedside.
    Fanali G; di Masi A; Trezza V; Marino M; Fasano M; Ascenzi P
    Mol Aspects Med; 2012 Jun; 33(3):209-90. PubMed ID: 22230555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A covalently linked recombinant albumin dimer is more rapidly cleared in vivo than are wild-type and mutant C34A albumin.
    McCurdy TR; Gataiance S; Eltringham-Smith LJ; Sheffield WP
    J Lab Clin Med; 2004 Feb; 143(2):115-24. PubMed ID: 14966467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human serum albumin.
    Chuang VT; Otagiri M
    Drugs Today (Barc); 2007 Aug; 43(8):547-61. PubMed ID: 17925886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physicochemical characterization of cross-linked human serum albumin dimer and its synthetic heme hybrid as an oxygen carrier.
    Komatsu T; Oguro Y; Teramura Y; Takeoka S; Okai J; Anraku M; Otagiri M; Tsuchida E
    Biochim Biophys Acta; 2004 Nov; 1675(1-3):21-31. PubMed ID: 15535964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The extraordinary ligand binding properties of human serum albumin.
    Fasano M; Curry S; Terreno E; Galliano M; Fanali G; Narciso P; Notari S; Ascenzi P
    IUBMB Life; 2005 Dec; 57(12):787-96. PubMed ID: 16393781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation of water-insoluble albumin film possessing nonadherent surface for cells and ligand binding ability.
    Yamazoe H; Tanabe T
    J Biomed Mater Res A; 2008 Jul; 86(1):228-34. PubMed ID: 17975816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ligand binding strategies of human serum albumin: how can the cargo be utilized?
    Varshney A; Sen P; Ahmad E; Rehan M; Subbarao N; Khan RH
    Chirality; 2010 Jan; 22(1):77-87. PubMed ID: 19319989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites.
    Curry S; Mandelkow H; Brick P; Franks N
    Nat Struct Biol; 1998 Sep; 5(9):827-35. PubMed ID: 9731778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An integrated in silico analysis of drug-binding to human serum albumin.
    Estrada E; Uriarte E; Molina E; Simón-Manso Y; Milne GW
    J Chem Inf Model; 2006; 46(6):2709-24. PubMed ID: 17125211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human plasma lipocalins and serum albumin: Plasma alternative carriers?
    di Masi A; Trezza V; Leboffe L; Ascenzi P
    J Control Release; 2016 Apr; 228():191-205. PubMed ID: 26951925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-carrying albumin film for blood-contacting biomaterials.
    Yamazoe H; Tanabe T
    J Biomater Sci Polym Ed; 2010; 21(5):647-57. PubMed ID: 20338098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.